REVIEW
|
doi:10.20944/preprints202401.0676.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
HER2; breast cancer; breast neoplasms; antibody-drug conjugate; ADCs; trastuzumab emtansine; trastuzumab deruxtecan; disitamab Vedotin; ARX-788; SYD985; BL-M0701; zanidatamab zovodotin.
Online: 9 January 2024 (10:29:59 CET)